Related Experiment Video
Updated: May 1, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Clinicopathologic study in uterine cancer
1Leuven Cancer Institute (LKI), Gynecologic Oncology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Abstract:
Patients with primary advanced or recurrent endometrial cancer are relatively uncommon and deserve better treatment options. Current treatment options are surgery, radiotherapy, and systemic therapy. Since the outcome is still poor, there is a need to improve our knowledge on molecular markers in order to personalize treatment. In addition, we need to continue the search for new treatment strategies with a better balance between efficacy and toxicity. In this doctoral thesis, we documented that among molecular and histological markers, blood vessel space involvement and chemotherapy induced regressive changes are new prognostic markers in endometrial cancer. We demonstrated that the tumour biology changes during tumour evolution. The optimal moment to decide on tumour biology is therefore the recurrent setting. A biopsy of the recurrent tumour is the best guarantee to characterize the tumour correctly. Furthermore, this study showed that neoadjuvant chemotherapy followed by interval debulking is a valuable treatment option for endometrial cancer with transperitoneal spread since optimal cytoreduction was achieved in 78% with a low morbidity. Future studies should look into new biomarkers that predict antitumoral activity and should search for mutations in endometrial cancer and analyse which mutation is sensitive for therapy.
Insights
New prognostic markers, including blood vessel involvement, improve endometrial cancer treatment personalization. Recurrent tumor biopsy and neoadjuvant chemotherapy offer valuable insights and therapeutic options for advanced cases.
Area of Science:
- Oncology
- Pathology
- Genitourinary Medicine
Background:
- Endometrial cancer, particularly advanced or recurrent forms, presents limited treatment options with poor outcomes.
- Personalized treatment strategies require a deeper understanding of molecular markers and tumor biology.
- Existing treatments include surgery, radiotherapy, and systemic therapy, necessitating improved efficacy and reduced toxicity.
Purpose of the Study:
- To identify novel prognostic markers for endometrial cancer.
- To investigate changes in tumor biology during disease evolution, especially in the recurrent setting.
- To evaluate the efficacy and safety of neoadjuvant chemotherapy followed by interval debulking for transperitoneal spread.
Main Methods:
- Analysis of molecular and histological markers in endometrial cancer patients.
- Characterization of tumor biology through recurrent tumor biopsy.
- Assessment of neoadjuvant chemotherapy and interval debulking surgery outcomes.
Main Results:
- Blood vessel space involvement and chemotherapy-induced regressive changes identified as new prognostic markers.
- Tumor biology demonstrated to evolve, making the recurrent setting crucial for accurate characterization.
- Neoadjuvant chemotherapy with interval debulking achieved optimal cytoreduction in 78% of patients with transperitoneal spread, with low morbidity.
Conclusions:
- Blood vessel space involvement and chemotherapy-induced regressive changes are significant prognostic markers in endometrial cancer.
- Biopsy of recurrent tumors is essential for accurate characterization due to evolving tumor biology.
- Neoadjuvant chemotherapy followed by interval debulking is a viable treatment for endometrial cancer with transperitoneal spread, achieving high cytoreduction rates.
More Related Videos
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023
08:09Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
Published on: July 25, 2017
